Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Loiselle

Radiation Oncology Seattle, WA Medical Doctor

NPI 1225259187 CMS profile 1110174

1221 Madison St, 1St Floor, Seattle, WA 98104

Open in the dashboard

General payments

$63,495

99 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$10,000 paid to institutions, not to them · program year 2024

Through program year 2025, Christopher Loiselle of Seattle, WA is reported in the CMS Open Payments database as having received $63,495 across 99 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $10,000 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Radiation Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,067 12
2024 General $8,377 18
2023 General $6,941 21
2022 General $29,546 32
2021 General $4,000 7
2020 General $4,500 8
2019 General $1,065 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Loiselle
  • Radiation Oncology median
  • Middle half of Radiation Oncology
  • National median

In program year 2025, general payments to Christopher Loiselle were reported at $9,067. Among 3,409 Radiation Oncology profiles paid that year, the median was $172 and the middle half received between $61 and $514.

Show as a table
Year Christopher Loiselle Radiation Oncology median Middle half National median
2019 $1,065 $138 $48–$462 $163
2020 $4,500 $79 $26–$262 $114
2021 $4,000 $119 $37–$358 $132
2022 $29,546 $139 $43–$424 $149
2023 $6,941 $167 $57–$473 $160
2024 $8,377 $168 $56–$541 $164
2025 $9,067 $172 $61–$514 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Accuray Incorporated $57,853 75 payments
  2. Brainlab, Inc. $4,963 14 payments
  3. RefleXion Medical, Inc. $329 1 payment
  4. Elekta, Inc. $184 7 payments
  5. AstraZeneca Pharmaceuticals LP $88 1 payment
  6. Siemens Medical Solutions USA, Inc. $78 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $21,078 34 payments
  2. Travel and Lodging $19,945 25 payments
  3. Consulting Fee $14,000 16 payments
  4. Honoraria $6,899 5 payments
  5. Food and Beverage $1,572 19 payments
Products named General payments · program years 2019–2025
  1. CyberKnife System Radiation Therapy $39,138 48 payments
  2. TomoTherapy System $17,947 20 payments
  3. CYBERKNIFE SYSTEM Radiation Oncology $10,061 18 payments
  4. CyberKnife System Devices $9,011 10 payments
  5. Surgical planning and navigation radiation treatment planning and positioning $3,223 7 payments
  6. Image Guided Surgical Device $1,739 7 payments
  7. REFLEXION MEDICAL RADIOTHERAPY SYSTEM $329 1 payment
  8. ELEKTA MEDICAL LINEAR ACCELERATOR $156 6 payments
  9. CALQUENCE $88 1 payment
  10. Varian Ethos Treatment Planning $78 1 payment
  11. Other $28 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

13

Median for Radiation Oncology: 65

Drug cost

$163

Median for Radiation Oncology: $978

Branded share of claims

0%

Median for Radiation Oncology: 7.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dexamethasone Generic 13 $163

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,680 Part D prescribers listed as Radiation Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$148,918

Medicare's payments for the services billed

Medicare patients

164

Average age 74

Services billed

1,921

100 women, 64 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 52%
Cancer 52%
Arthritis 46%
Depression 24%
Osteoporosis 20%
Diabetes 15%
Ischemic heart disease 15%
COPD 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

99 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record